The phase III INAVO120 trial showed that in patients with PIK3CA-mutated, HR+ HER2- advanced breast cancers, treatment with inavolisib (plus palbociclib and fulvestrant) led to a significant overall survival benefit, although adverse effects were more frequent with inavolisib [15]. This evidence concerns the gene ERBB2 and breast carcinoma.